Management of infections in the ICU and the role of novel antibiotics
Date: 17 July 2021
Time: 1200 – 1300
Critical care specialists often face challenges in managing multidrug resistant organisms in the ICU. This presentation covers the factors influencing empiric treatment choice, consequences of delayed and inappropriate therapy, and the role of newer antimicrobial agents.
To provide updates on the management of infections in the ICU and the role of novel antibiotics
1200–1245 – Presentation
1245–1300 – Q&A Session
Prof Andrew Shorr, USA
Dr. Shorr is currently Head, Pulmonary and Critical Care Medicine at Medstar Washington Hospital Center and a Professor of Medicine at Georgetown Univ. He serves as the medical director for the Medical ICU and for Respiratory Therapy. He earned his undergraduate degree in Public Policy at Princeton Univ. He obtained his medical degree at the Univ. of Virginia. He also holds an MPH from Johns Hopkins Univ and an MBA from the Univ of Virginia. He completed his training in internal medicine, pulmonary medicine, and critical care at Walter Reed Army Medical Center. Dr Shorr is a fellow of both the American College of Physicians and the American College of Chest Physician. His research focuses on issues related to severe pneumonia, health economics, and epidemiology. In addition to being a Fullbright Specialist, he has won multiple awards for his bedside teaching and his research.
The ICU environment can negatively affect patients, families and staff and contribute to potentially preventable adverse outcomes. This presentation describes a co-design project that is reconceptualising the ICU bedspace environment into a patient-centred, flexible healing environment that promotes recovery.
To describe the current ICU environment, its impact on patients, family and staff, and how using evidence-based design and innovative technologies can address identified problems and improve patient experience and outcomes.
Prof John Fraser (MB ChB, PhD, FRCP (Glas), FFARCSI, FRCA, FCICM) is the Director of the Critical Care Research Group at The Prince Charles Hospital and University of Queensland and Director of the Intensive Care Unit at St Andrew’s War Memorial Hospital.
Following his PhD in ‘fetal wound healing’, Dr Fraser started the Critical Care Research Group at Australia’s largest cardiac centre’, The Prince Charles Hospital.
The Group has now developed to almost 90 staff and 8 labs. Being awarded the first international Centre for Research Excellence in mechanical support, the CCRG has become popular with over 25 nationalities represented.
Dr Fraser is also President of APELSO and Chair of the Queensland Cardiovascular Research Network, and a founding member of ECMO net, and on the global board of ELSO. He has published over 450 manuscripts, and the PI behind the COVID Consortium, collating data from over 54 countries into an IBM-created dashboard distributed freely across the globe to ICU clinicians to assist them in decision making through the provision of aggregate data.
Oystein Tronstad is a physiotherapy clinical lead at The Prince Charles Hospital with a special interest in patient-centred care, investigating how the multi-disciplinary team can maximise short and long-term recovery of ICU survivors. Stein is currently leading the ICU of the Future project, investigating how the ICU environment and design is affecting patient outcomes, aiming to redesign the ICU bedspace around the needs of the patients.
Suspecting, diagnosing and treating invasive mould infections in the ICU
Date: 18 July 2021
Time: 1230 – 1330
Other than neutropenic patients, invasive aspergillosis is increasingly observed in hosts with less traditional risk factors. Almost half of all cases of invasive aspergillosis occur in the ICU. This presentation covers the diagnosis and factors influencing treatment choice for invasive mould infections in the ICU.
To provide an update on invasive mould infections in the ICU, with a focus on the role of diagnostic tools and treatment options.
1230–1315 – Presentation
1315–1330 – Q&A Session
Prof Malgorzata Mikulska, Italy
Malgorzata Mikulska is an Associate Professor of Infectious Diseases at the University of Genova (Department of Health Sciences, DISSAL) since 2015, and full time Infectious Diseases Consultant at the Division of Infectious Diseases since 2012, IRCCSS Ospedale Policlinico San Martino in Genova, Italy.
She obtained her medical degree at Warsaw Medical University, Poland, subsequently recognized in 2005 by the University of Genova. She completed her specialty training in Infectious Diseases at the University of Genova in 2008 and obtained PhD degree at Università Cattolica di Roma in 2011, Italy.
She is an author or co-author of over 100 documents, mostly indexed international medical journals, with Hindex of 29. She is also a co-author of 7 book chapters, including the one of Prophylaxis and Empirical Therapy of Infections in Cancer Patients in “Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases”, 9th Edition. By John E. Bennett, Raphael Dolin, Martin J. Blaser. Elsevier 2020.
She is a reviewer for several international journals and an active member of the following scientific societies:
Secretary of Infectious Diseases Working Party (IDWP) of EBMT (The European Group for Blood and
Marrow Transplantation) for years 2016-2020
European Conference on Infections in Leukemia (ECIL) group since 2009
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Infectious Diseases Member of Professional Affaires Committee (PAS) of ESCMID
ESCMID Study Group for Infections in Compromised Hosts (ESGIH) since 2011
ESCMID Fungal Infection Study Group Study Group (EFISG) since 2013
Academy Committee of ECMM (European Confederation of Medical Mycology)
Italian society of Infectious diseases and Tropical Medicine (SIMIT)
Italian Federation of Human and animal Mycopathology (FIMUA) since 2008
Her principal areas of expertise are infections in immunocompromised patients, in particular in patients with haematological disorder and allogeneic haematopoietic stem cell transplant (HSCT) recipients, and diagnosis and treatment of invasive fungal infections.